# Teplizumab in Pediatric Stage 2 Type 1 Diabetes

> **NCT05757713** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 20 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** teplizumab

## Key facts

- **NCT ID:** NCT05757713
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-25
- **Primary completion:** 2026-08-27
- **Final completion:** 2026-08-27
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05757713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05757713, "Teplizumab in Pediatric Stage 2 Type 1 Diabetes". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05757713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*